CHANNELS

Subscribe to the InfoTech eNewsletter

infoTECH News

TMCNet:  Research and Markets: Global Macular Edema Market 2014-2018 with Bayer AG, F. Hoffmann-La Roche, Novartis & Regeneron Pharmaceuticals Dominating

[August 12, 2014]

Research and Markets: Global Macular Edema Market 2014-2018 with Bayer AG, F. Hoffmann-La Roche, Novartis & Regeneron Pharmaceuticals Dominating

DUBLIN --(Business Wire)--

Research and Markets (http://www.researchandmarkets.com/research/jqtw8n/global_macular) has announced the addition of the "Global Macular Edema Market 2014-2018" report to their offering.

The Global Macular Edema market will grow at a CAGR of 9.1% over the period 2014-2018.

NICE issues and updates technology appraisals and clinical guidelines to recommend appropriate and effective treatments for different diseases. It plays a role in increasing drug sales. In January 2013, NICE recommended Lucentis for the treatment of DME. This recommendation superseded the November 2011 guidance, which concluded that recommending Lucentis was not effective utilization of NHS resources. Lucentis has also been recommended for the treatment of vision impairment as a result of macular edema associated with RVO

According to the report, the Global Macular Edema market is driven by several factors, of which the increase in the patient population is one of the major drivers. Eye diseases such as DR, retinal dystrophies, AMD (News - Alert), inflammatory conditions such as uveitis, and RVO cause macular edema. The increase in the incidence and prevalence of ophthalmological conditions such as AMD and DR is expected to increase the patient population with macular edema during the forecast period.

Further, the report states that although the Global Macular Edema market has several drivers, the growth of the market is curtailed by some serious challenges. One of the main challenges is increased use of off-label drugs. Use of off-label drugs increases the market competition for approved branded drugs. Some of the off-label drugs for the treatment of macular edema are bevacizumab, topical NSAIDs, and drugs such as acetazolamide.

The report also includes a discussion of the other vendors operating in this market. The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

Key Vendors

  • Bayer AG
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • Regeneron Pharmaceuticals Inc.

Other Prominent Vendors

  • Alcon Inc.
  • Alimera Sciences Inc.
  • Allergan Inc.
  • Ampio Pharmaceuticals Inc.
  • iCo Therapeutics Inc.
  • Pfizer Inc.
  • Santen Pharmaceutical Co. Ltd.

For more information visit http://www.researchandmarkets.com/research/jqtw8n/global_macular


[ InfoTech Spotlight's Homepage ]


blog comments powered by Disqus

FOLLOW US

Subscribe to InfoTECH Spotlight eNews

InfoTECH Spotlight eNews delivers the latest news impacting technology in the IT industry each week. Sign up to receive FREE breaking news today!
FREE eNewsletter